BR0206853A - Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antagonistas de receptor de endotelina ou tienopirimidinas e antagonistas de receptor de endotelina - Google Patents

Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antagonistas de receptor de endotelina ou tienopirimidinas e antagonistas de receptor de endotelina

Info

Publication number
BR0206853A
BR0206853A BR0206853-2A BR0206853A BR0206853A BR 0206853 A BR0206853 A BR 0206853A BR 0206853 A BR0206853 A BR 0206853A BR 0206853 A BR0206853 A BR 0206853A
Authority
BR
Brazil
Prior art keywords
endothelin receptor
receptor antagonists
pyrimidines
failure
pharmaceutical formulation
Prior art date
Application number
BR0206853-2A
Other languages
English (en)
Inventor
Hans-Michael Eggenweiler
Volker Eiermann
Pierre Schelling
Original Assignee
Merck Patent Ges Mit Beschroen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001104800 external-priority patent/DE10104800A1/de
Priority claimed from DE2001104801 external-priority patent/DE10104801A1/de
Priority claimed from DE2001104802 external-priority patent/DE10104802A1/de
Application filed by Merck Patent Ges Mit Beschroen filed Critical Merck Patent Ges Mit Beschroen
Publication of BR0206853A publication Critical patent/BR0206853A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"FORMULAçãO FARMACêUTICA COMPREENDENDO PIRAZOLO[4,3-D]PIRIMIDINAS E ANTAGONISTAS DE RECEPTOR DE ENDOTELINA OU TIENOPIRIMIDINAS E ANTAGONISTAS DE RECEPTOR DE ENDOTELINA". A presente invenção refere-se a preparação farmacêutica compreendendo pelo menos um inibidor de fosfodiesterase V tem, e/ou sal fisiologicamente aceitável e/ou solvatos deste e pelo menos um antagonista de receptor de endotelina para a preparação de um medicamento para o tratamento de angina, pressão sang³ínea alta, pressão pulmonar alta, insuficiência cardíaca congestiva (CHF), doença pulmonar obstrutiva crónica (COPD), coração pulmonar, insuficiência dextrocardíaca, aterosclerose, condições de patência reduzida dos vasos cardíacos, doenças vasculares periféricas, acidentes vasculares cerebrais, bronquite, asma alérgica, asma crónica, rinite alérgica, glaucoma, síndrome de intestino irritável, tumores, insuficiência renal, cirrose hepática, disfunção erétil e para o tratamento de distúrbios sexuais femininos.
BR0206853-2A 2001-02-02 2002-01-14 Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antagonistas de receptor de endotelina ou tienopirimidinas e antagonistas de receptor de endotelina BR0206853A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE2001104800 DE10104800A1 (de) 2001-02-02 2001-02-02 Pharmazeutische Formulierungen enthaltend Pyrazolo[4,3-d]pyrimidine und Endothelin-Rezeptor-Antagonisten
DE2001104801 DE10104801A1 (de) 2001-02-02 2001-02-02 Pharmazeutische Formulierungen enthaltend Thienopirimidine und Endothelin-Rezeptor-Antagonisten (2)
DE2001104802 DE10104802A1 (de) 2001-02-02 2001-02-02 Pharmazeutische Formulierungen enthaltend Thienopirimidine und Endothelin-Rezeptor-Antagonisten (1)
PCT/EP2002/000256 WO2002062343A2 (en) 2001-02-02 2002-01-14 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
BR0206853A true BR0206853A (pt) 2004-01-13

Family

ID=27214266

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206853-2A BR0206853A (pt) 2001-02-02 2002-01-14 Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antagonistas de receptor de endotelina ou tienopirimidinas e antagonistas de receptor de endotelina

Country Status (13)

Country Link
US (1) US20040063731A1 (pt)
EP (1) EP1357915A2 (pt)
JP (1) JP2004525890A (pt)
KR (1) KR20030071880A (pt)
CN (1) CN1489467A (pt)
BR (1) BR0206853A (pt)
CA (1) CA2437085A1 (pt)
CZ (1) CZ20032350A3 (pt)
HU (1) HUP0303005A3 (pt)
MX (1) MXPA03006802A (pt)
PL (1) PL362510A1 (pt)
SK (1) SK10782003A3 (pt)
WO (1) WO2002062343A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
WO2006055573A2 (en) * 2004-11-18 2006-05-26 Schering Corporation Methods of using pde v inhibitors for the treatment of congestive heart failure
WO2008088727A2 (en) 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
SE542968C2 (en) 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis
WO2021087399A1 (en) * 2019-10-30 2021-05-06 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
EP4100406A4 (en) 2020-02-06 2023-07-05 Perfuse Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF OCULAR DISEASES
AU2022264036A1 (en) 2021-04-30 2023-11-23 Perfuse Therapeutics, Inc. Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
DE19632423A1 (de) * 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidine
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
DE19709877A1 (de) * 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US6268388B1 (en) * 1997-08-22 2001-07-31 Bristol-Myers Squibb Company Method for preventing or treating erectile dysfunction by administering an endothelin antagonist
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
AU3713600A (en) * 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use

Also Published As

Publication number Publication date
MXPA03006802A (es) 2003-11-13
WO2002062343A2 (en) 2002-08-15
KR20030071880A (ko) 2003-09-06
HUP0303005A3 (en) 2005-05-30
HUP0303005A2 (hu) 2003-12-29
WO2002062343A3 (en) 2002-11-21
EP1357915A2 (en) 2003-11-05
CA2437085A1 (en) 2002-08-15
CZ20032350A3 (en) 2004-03-17
CN1489467A (zh) 2004-04-14
SK10782003A3 (sk) 2003-12-02
PL362510A1 (en) 2004-11-02
JP2004525890A (ja) 2004-08-26
US20040063731A1 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
BR0206853A (pt) Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antagonistas de receptor de endotelina ou tienopirimidinas e antagonistas de receptor de endotelina
HUP0303315A2 (hu) Pirazolo [4,3-d] pirimidineket és trombózisellenes szereket, kalcium antagonistákat, prosztaglandinokat vagy prosztaglandinszármazékokat tartalmazó gyógyszerkészítmények
HUP0400818A2 (hu) Tieno[2,3-d]pirimidinek alkalmazása és az ezeket tartalmazó gyógyszerkészítmények
JP2000001434A (ja) コルチコトロピン放出因子アンタゴニストを含む医薬組成物
TNSN07050A1 (fr) Derives de triazolopyridinylsulfanyle servant d'inhibiteurs de kinase map p38
GEP20105025B (en) Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases
KR20010014678A (ko) 돌연사 방지를 위하여 ｃｒｆ 길항제를 이용한 ｑｔ 분산및 심박수 변동성의 개선
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
US8552016B2 (en) Anti-cancer cyclopenta(g)quinazoline compounds
JP2023518974A (ja) コロナウイルス感染症による化学感覚機能障害の治療
MD523G2 (ro) Derivaţi noi ai triazolpirimidinei, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
WO2002081728A3 (en) Quinoline inhibitors of hyak1 and hyak3 kinases
BR0116849A (pt) Formulações farmacêuticas compreendendo pirazolo[4,3-d]pirimidinas e nitratos ou tienopirimidinas e nitratos
KR20040040457A (ko) 폐질환 치료방법
EP1949893A3 (en) Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
EP0662834A1 (en) Novel epoxide-containing compounds
RU2002118304A (ru) Способ подавления чувства страха
BR0116255A (pt) Formulação farmacêutica compreendendo tienopirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas e derivados de prostaglandina (1)
BR0211938A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do dito composto ou de um sal ou solvato farmaceuticamente aceitável do mesmo, e, método para tratar os distúrbios de fertilidade em pacientes em necessidade do mesmo
BR0115187A (pt) Uso de pirazolo[4,3-d]pirimidinas
WO2003020300A1 (en) Use of cyclopenta[g]quinazoline derivatives for treating cancer
US10603321B2 (en) Small molecules targeting HIV-1 nef
ES2384715T3 (es) Fumarato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo
HUP0401368A2 (hu) Tienopirimidineket és trombózisellenes szereket, kalcium antagonistákat, prosztaglandinokat vagy prosztaglandin származékokat tartalmazó gyógyszerkészítmények
TH55360B (th) สูตรผสมทางเภสัชกรรมซึ่งประกอบรวมด้วยไพราโซโล[4, 3-d]ไพริมิดีนและแอนตะกอนิสต์ของตัวรับเอนโดทีลิน หรือไทอีโนไพริมิดีนและแอนตะกอนิสต์ของตัวรับเอนโดทีลิน

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]